BioSpace News Archive

Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.

The FDA noted that the EUA application for Novavax’s COVID-19 shot may take a while to be resolved, citing an “incredibly complex review process.”

Ampio shares continue to fall following the company’s announcement that the FDA rejected proposed changes to a Phase III study of its treatment for osteoarthritis of the knee and other joints.

COVID-19 continues to generate surprises, such as a possible link between dementia and severe COVID-19. Continue reading for that and more research stories.

Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.

Orasis Pharmaceuticals announced that its eye drop candidate CSF-1 met all primary and key secondary endpoints in Phase III clinical trials. CSF-1 is intended to treat presbyopia.

GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, added a record five pharmacogenetic companies as customers in the first quarter of 2022.

Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on April 20, 2022 to close the consolidated financial statements for the year ending December 31, 2021, announces its full-year results for 2021 and business indicators for the first quarter of 2022.

Guerbet, a global specialist in contrast agents and solutions for medical imaging, reports its revenue for first-quarter 2022.

C2N Diagnostics, a leader in advanced brain health diagnostics, announced today that the Journal of the American Medical Association Network Open, a peer-reviewed medical journal from the American Medical Association, has published the combined results from two independent studies for the PrecivityAD™ blood test, which aids healthcare providers in diagnosing Alzheimer’s disease.